Human genome-produced RNA discovered on surface of cells
Human genome-produced RNA has been found on the surface of human cells, which researchers say could be easier for therapeutics to reach.
List view / Grid view
Human genome-produced RNA has been found on the surface of human cells, which researchers say could be easier for therapeutics to reach.
An analysis of blood protein levels has supported drug target prioritisation by identifying the causal effects of proteins on diseases, a team has shown.
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
By analysing the expression of 28 genes, researchers have been able to identify which organs are most vulnerable to infection from COVID-19.
Scientists observed that different cancers undergo the same genetic mutations at similar stages of evolution, the findings could become part of an ‘evolutionary rule book’ which would theoretically enable the prediction and prevention of cancer’s next evolutionary move.
A genetic analysis of SARS-CoV-2 sequences reveal the virus has mutated minimally since December 2019, suggesting only one vaccine is needed to combat COVID-19.
Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
Computational analysis has been used by researchers to examine 66 types of cancer and identify 568 genes that drive tumour development.
A team has found that a mutation in the ATAXIN-1 gene causes spinocerebellar ataxia type 1 (SCA1), presenting a drug target for the condition.
A machine learning algorithm that predicts sites of DNA methylation could aid in the identification of disease-causing mechanisms, say researchers.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry. However, characterisation of oligos, specifically by ion-pair reversed phase liquid chromatography (IPRPLC), can be quite challenging.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
Silencing RNA, or siRNA, are short, double-stranded RNA molecules which are not only an important research tool in molecular biology, but also an emerging therapeutic modality.
Superficially porous particle technologies provide a reduced diffusion path in comparison with their fully porous counterparts minimising the resistance to mass transfer during chromatographic separation.